Inactive Instrument

Press Releases 4D pharma plc

Equities

DDDD

GB00BJL5BR07

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) - Form 6-K	22-11-15	PU
4D pharma : Presents at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)	22-11-10	PU
4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) - Form 6-K	22-10-07	PU
4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)	22-10-05	PU
4D pharma : Publication of Joint Administrators’ Proposals - Form 6-K	22-08-24	PU
4D PHARMA : “4D pharma”) RECEIVES NOTICE OF DELISTING FROM NASDAQ - Form 6-K	22-06-29	PU
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq	22-06-28	BU
Update on Suspension of Trading	22-06-24	BU
4D pharma presents trial in progress poster on the Phase II Study of MRx0518 in combination with BAVENCIO(R) in patients with unresectable locally advanced or metastatic urothelial carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	22-05-27	AQ
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	22-05-26	BU
4D pharma to Present at the H.C. Wainwright Global Investment Conference	22-05-19	BU
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference	22-05-17	BU
4D pharma : Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 - Form 6-K	22-04-04	PU
4D pharma : Annual Report and Account for the year ended 31 December 2021	22-04-01	PU
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022	22-03-31	BU
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA (pembrolizumab) for the Treatment of Renal Cell Carcinoma	22-03-23	AQ
4D pharma : Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma - Form 6-K	22-03-23	PU
4D pharma : Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma	22-03-23	PU
4D pharma : Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma	22-03-23	PU
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit	22-02-23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 4D pharma plc

Equities

DDDD

GB00BJL5BR07

Press Releases

Filters